罗格列酮上调成人隐匿性自身免疫糖尿病患者CD4+T细胞Foxp3 mRNA的表达

目的 观察罗格列酮对成人隐匿性自身免疫糖尿病(LADA)患者CD4+调节性T细胞的影响,旨在探讨罗格列酮的免疫调节机制.方法 采用磁珠分离LADA患者CD4+T细胞,1、10和100 μmol/L罗格列酮干预CIM+T细胞.MTT法检测细胞活性,3H-TdR掺人法检测增殖抑制率.流式细胞术检测CD4+CD25+T细胞比值.RT-PCR检测过氧化物酶体增殖激活受体-γ(PPARγ)mRNA、TGF-β1 mRNA表达,实时荧光定量PCR检测Foxp3 mRNA表达.结果 CD4+T细胞表达PPARγmRNA.罗格列酮抑制植物凝集素(PHA)刺激的CD4+T细胞增殖.1μmol/L和10μmol/L组罗格列酮作用的CD4+CD25+T细胞比例无明显变化,100 μmol/L组CD4+CD25+T细胞比例降低.10μmol/L罗格列酮上调CD4+T细胞的Foxp3 mRNA表达,但TGF-β1 mRNA表达无显著变化.小剂量IL-2参与下,1μmol/L罗格列酮(药理浓度范围内)升高CD4+T细胞Foxp3mRNA表达.结论 罗格列酮上调LADA患者CD4+T细胞Foxp3 mRNA表达,改善自身免疫耐受缺陷.

Rosiglitazone upregulates Foxp3 mRNA expression of CD4+T cells in adults with latent autoimmune diabetes

Objective To investigate the effect of rosiglitazone on the CD4+regulatory T cells in the patients with latent autoimmune diabetes in adults(LADA).Methods The CIM+T cells from IADA patients were isolated with anti-CD4-dynal magnetic beads.The expression of Foxp3 mRNA,along with peroxisome proliferators activator receptors gamma(PPARγ)mRNA and TGF-131 mRNA was determined.The effect of rosiglitazone on CD4+T cells was measured,after treated with rosiglitazone for 48 h.Cell viability was assessed by Mtit assay.The proliferation was assayed with 3 H-TdR.Two-color staining(anti-CD4,anti-CD25)flow cytometric analysis was employed to measure the percentage of CD4+CD25+T cells of Deriph eral blood.Resuits PPARγmRNA was expressed in peripheral CD4+T lymphocytes.RosiglitazoBe inhibited phytohemagglutinin(PHA)-induced human CD4+T cell proliferation in dose dependence.The percentage of CD4+CD25+T cells showed no significant change after the peripheral blood culture with 1 μmol/Land 10μmot/L rosiglitazone.10 μmol/L of rosiglitazone induced Foxp3 mRNA expression in vitro (3.27fold,P<0.05),whereas TGF-β1 mRNA expression did not change.Furthermore,only 1 μmol/L of rosiglitazone could promote Foxp3 mRNA expression if adding IL-2(10 U/m1)in cultures(3.48 fold.P